In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae

Patricia M Roblin; Tamara Reznik; Margaret R Hammerschlag

doi:10.1016/s0924-8579(03)00061-x

In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae

Int J Antimicrob Agents. 2003 Jun;21(6):578-80. doi: 10.1016/s0924-8579(03)00061-x.

Authors

Patricia M Roblin¹, Tamara Reznik, Margaret R Hammerschlag

Affiliation

¹ Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Box 49, 450 Clarkson Avenue, Brooklyn, NY 11203-2098, USA.

PMID: 12791473
DOI: 10.1016/s0924-8579(03)00061-x

Abstract

The in vitro activities of garenoxacin, a novel des-F (6)-quinolone, levofloxacin, moxifloxacin and clarithromycin were tested against 30 recent clinical isolates of Chlamydia pneumoniae. The minimal inhibitory concentration (MIC) at which 90% of the isolates were inhibited and the minimal bactericidal concentration (MBC) at which 90% of the isolates were killed by garenoxacin for C. pneumoniae was 0.03 mg/l (range 0.015-0.03 mg/l).

MeSH terms

Adult
Anti-Infective Agents / pharmacology*
Canada
Chlamydophila Infections / microbiology*
Chlamydophila pneumoniae / drug effects*
Chlamydophila pneumoniae / isolation & purification
Community-Acquired Infections / microbiology
Fluoroquinolones*
Humans
Indoles / pharmacology*
Japan
Microbial Sensitivity Tests
Pneumonia, Bacterial / microbiology
Quinolones / pharmacology*
United States

Substances

Anti-Infective Agents
Fluoroquinolones
Indoles
Quinolones
garenoxacin